BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone919-582-9050
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$61.99 million
Profitability
Miscellaneous
Employees116
OptionableOptionable
BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions
What is BioDelivery Sciences International's stock symbol?
BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."
How were BioDelivery Sciences International's earnings last quarter?
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its quarterly earnings data on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The specialty pharmaceutical company earned $12.18 million during the quarter, compared to analyst estimates of $12.44 million. BioDelivery Sciences International had a negative net margin of 85.93% and a negative return on equity of 141.35%. View BioDelivery Sciences International's Earnings History.
When is BioDelivery Sciences International's next earnings date?
What price target have analysts set for BDSI?
4 brokers have issued 1-year price objectives for BioDelivery Sciences International's shares. Their predictions range from $4.00 to $5.00. On average, they anticipate BioDelivery Sciences International's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price. View Analyst Price Targets for BioDelivery Sciences International.
What is the consensus analysts' recommendation for BioDelivery Sciences International?
What are Wall Street analysts saying about BioDelivery Sciences International stock?
Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
- 1. Cantor Fitzgerald analysts commented, "We view BDSI as a Belbuca execution story, and, based on Symphony script data, the company is exceeding its execution goals as well as our expectations. Execution, as well as increased access for Belbuca going into 2019 have increased our conviction that solid execution in 2019 and beyond is likely to continue, which should drive upward earnings revisions and further upside in BDSI stock. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $5.00." (2/8/2019)
- 2. According to Zacks Investment Research, "BioDelivery secured improved positioning in several managed care contracts providing preferred access to Belbuca. The company’s efforts has brought 100 million patients under preferred coverage so far this year, having started the year with 7 million. This has already started to boost the drug’s sales and profitability in 2018. Belbuca’s prescriptions has grown sequentially every quarter in 2018. Increase in sales force has supported the growth. BioDelivery’s shares have outperformed the industry in the past six months. However, given the lackluster performance of Bunavail, BioDelivery decided to reduce spending on the drug. Moreover, the company’s portfolio as well as its pipeline candidates may also face severe competition as it targets a highly genericized and crowded market. Estimates have remained stable ahead of Q4 earnings. BioDelivery has a positive record of earnings surprises in the recent quarters." (1/23/2019)
- 3. HC Wainwright analysts commented, "Our $5, 12-month price target is based on a DCF reflecting strong Belbuca growth to over $150M by 2022, cash- flow breakeven by end-2019, and overall profitability in 2020. Our DCF reflects a 10.5% WACC discount and negative -15% terminal value beyond 2027, and includes 93M shares (post-financing, plus other currently anti-dilutive shares)." (11/2/2018)
Has BioDelivery Sciences International been receiving favorable news coverage?
Headlines about BDSI stock have trended very positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioDelivery Sciences International earned a media sentiment score of 3.3 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of BioDelivery Sciences International's key competitors?
Some companies that are related to BioDelivery Sciences International include Cambrex (CBM), Spectrum Pharmaceuticals (SPPI), Phibro Animal Health (PAHC), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA), Puma Biotechnology (PBYI), Deciphera Pharmaceuticals (DCPH), Rhythm Pharmaceuticals (RYTM), Epizyme (EPZM), Alder Biopharmaceuticals (ALDR), Tricida (TCDA), Kiniksa Pharmaceuticals (KNSA) and MacroGenics (MGNX).
Who are BioDelivery Sciences International's key executives?
BioDelivery Sciences International's management team includes the folowing people:
- Mr. Ernest Robert De Paolantonio CPA, MBA, CFO & Treasurer (Age 65)
- Mr. Herm Cukier, CEO & Director (Age 52)
- Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 54)
- Mr. Joseph M. Lockhart, Sr. VP of Operations
- Ms. Mary Coleman, VP of Investor & PR
Who are BioDelivery Sciences International's major shareholders?
BioDelivery Sciences International's stock is owned by a number of of institutional and retail investors. Top institutional investors include venBio Select Advisor LLC (6.67%), Stonepine Capital Management LLC (5.62%), Nantahala Capital Management LLC (3.86%), BlackRock Inc. (1.96%), Millennium Management LLC (1.39%) and 1492 Capital Management LLC (1.25%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht and Paolantonio Ernest Robert De. View Institutional Ownership Trends for BioDelivery Sciences International.
Which institutional investors are selling BioDelivery Sciences International stock?
BDSI stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Stonepine Capital Management LLC, Fosun International Ltd, Foresite Capital Management II LLC and Essex Investment Management Co. LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Mark A Sirgo and Paolantonio Ernest Robert De. View Insider Buying and Selling for BioDelivery Sciences International.
Which institutional investors are buying BioDelivery Sciences International stock?
BDSI stock was purchased by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Millennium Management LLC, Pura Vida Investments LLC, 1492 Capital Management LLC, Barclays PLC, D. E. Shaw & Co. Inc., BlackRock Inc. and Emerald Advisers LLC. View Insider Buying and Selling for BioDelivery Sciences International.
How do I buy shares of BioDelivery Sciences International?
Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioDelivery Sciences International's stock price today?
One share of BDSI stock can currently be purchased for approximately $4.63.
How big of a company is BioDelivery Sciences International?
BioDelivery Sciences International has a market capitalization of $327.85 million and generates $61.99 million in revenue each year. The specialty pharmaceutical company earns $5.28 million in net income (profit) each year or ($0.39) on an earnings per share basis. BioDelivery Sciences International employs 116 workers across the globe.
What is BioDelivery Sciences International's official website?
How can I contact BioDelivery Sciences International?
BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]
MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
